Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Clinical Pharmacology in Drug Development
|
November 16, 2021
Phase 1 Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects With Actinic Keratosis
Regina Yavel, J Scott Overcash, David Cutler, et al.
Future Microbiology
|
May 7, 2021
Efficacy and safety of ceftobiprole in patients aged 65 years or older: a <i>post hoc</i> analysis of three Phase III studies
Tobias Welte, Thomas Wl Scheeren, J Scott Overcash, et al.
Antimicrobial Agents and Chemotherapy
|
August 5, 2020
Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid
Frederick Wittke, Catherine Vincent, James Chen, et al.
Antimicrobial Agents and Chemotherapy
|
March 13, 2019
Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
J Scott Overcash, Pouru Bhiwandi, Lynne Garrity-Ryan, et al.
Antimicrobial Agents and Chemotherapy
|
December 19, 2018
Bone and Joint Tissue Penetration of the <i>Staphylococcus</i>-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery
Annick Menetrey, Annick Janin, John Pullman, et al.
Antimicrobial Agents and Chemotherapy
|
April 15, 2020
Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis)
J Scott Overcash, Courtney A Tiffany, Nicole E Scangarella-Oman, et al.
The Journal of Antimicrobial Chemotherapy
|
March 28, 2025
Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials
Thomas L Holland, Andrew F Shorr, J Scott Overcash, et al.
The New England Journal of Medicine
|
June 5, 2014
Single-dose oritavancin in the treatment of acute bacterial skin infections
G Ralph Corey, Heidi Kabler, Purvi Mehra, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 27, 2022
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study
Fred Poordad, Franco Felizarta, Betty B Yao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 28, 2017
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1
David B Huang, William O'Riordan, J Scott Overcash, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Clinical Pharmacology in Drug Development
|
November 16, 2021
Phase 1 Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects With Actinic Keratosis
Regina Yavel, J Scott Overcash, David Cutler, et al.
Future Microbiology
|
May 7, 2021
Efficacy and safety of ceftobiprole in patients aged 65 years or older: a <i>post hoc</i> analysis of three Phase III studies
Tobias Welte, Thomas Wl Scheeren, J Scott Overcash, et al.
Antimicrobial Agents and Chemotherapy
|
August 5, 2020
Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid
Frederick Wittke, Catherine Vincent, James Chen, et al.
Antimicrobial Agents and Chemotherapy
|
March 13, 2019
Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
J Scott Overcash, Pouru Bhiwandi, Lynne Garrity-Ryan, et al.
Antimicrobial Agents and Chemotherapy
|
December 19, 2018
Bone and Joint Tissue Penetration of the <i>Staphylococcus</i>-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery
Annick Menetrey, Annick Janin, John Pullman, et al.
Antimicrobial Agents and Chemotherapy
|
April 15, 2020
Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis)
J Scott Overcash, Courtney A Tiffany, Nicole E Scangarella-Oman, et al.
The Journal of Antimicrobial Chemotherapy
|
March 28, 2025
Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials
Thomas L Holland, Andrew F Shorr, J Scott Overcash, et al.
The New England Journal of Medicine
|
June 5, 2014
Single-dose oritavancin in the treatment of acute bacterial skin infections
G Ralph Corey, Heidi Kabler, Purvi Mehra, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 27, 2022
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study
Fred Poordad, Franco Felizarta, Betty B Yao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 28, 2017
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1
David B Huang, William O'Riordan, J Scott Overcash, et al.
Page
of 3